deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04605094

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)

Sponsor: AstraZeneca

Conditions Atopic Dermatitis
Interventions Benralizumab Placebo / Benralizumab
Updated 24 times since 2020 Last updated: Aug 30, 2023 Started: Nov 12, 2020 Primary completion: Apr 25, 2022 Completion: Sep 13, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study did not meet the primary endpoint.

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Atopic Dermatitis trials with similar outcome

Browse all Atopic Dermatitis trials

A PHASE2 clinical study on Atopic Dermatitis, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 24 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jul 2023 — Sep 2023 [monthly]

    Terminated PHASE2

▶ Show 19 earlier versions

  1. Feb 2023 — Jul 2023 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  2. Nov 2022 — Feb 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  9. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  10. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  11. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  12. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  13. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  14. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  15. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  16. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  17. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  18. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  19. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Iqvia Pty Ltd
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Ansan-si, South Korea , Barcelona, Spain , Brest, France , Bridgeport, United States , Brno, Czechia , Cincinnati, United States , Córdoba, Spain , Daegu, South Korea , Fort Myers, United States and 32 more locations